Trials / Not Yet Recruiting
Not Yet RecruitingNCT05979220
Study of Dalpiciclib Combined With Letrozole in the Maintenance Treatment of HR Positive and HER2 Negative Metastatic Breast Cancer After First-line Chemotherapy
A Multicenter, Single Arm, Prospective Phase II Clinical Study of Dalpiciclib Combined With Letrozole in the Maintenance Treatment of HR Positive and HER2 Negative Metastatic Breast Cancer After First-line Chemotherapy
- Status
- Not Yet Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 178 (estimated)
- Sponsor
- Shuangyue Liu · Academic / Other
- Sex
- Female
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This study aimed to evaluate the efficacy and safety of Dalpiciclib combined with Letrozole in the maintenance treatment of HR positive and HER2 negative metastatic breast cancer after first-line chemotherapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Dalpiciclib combined with Letrozole | A multicenter, single arm, prospective Phase II clinical study |
Timeline
- Start date
- 2023-12-01
- Primary completion
- 2024-06-30
- Completion
- 2028-06-30
- First posted
- 2023-08-07
- Last updated
- 2023-08-07
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05979220. Inclusion in this directory is not an endorsement.